Drug intelligence / Profile preview

RT4327

Development stage: Preclinical
Lead developer: Nanjing RegeneCore Biotech
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Intravenous, Intratumoral

Overview

RT4327 is an investigational therapeutic candidate currently in preclinical development by Nanjing Regenecore Biotech (also known as Nanjing Chongyuan Biotechnology) for the treatment of solid tumors. The drug is developed using the company's proprietary mRNA technology platform, which focuses on creating mRNA-based therapeutics for oncology and regenerative medicine. While RT4327 is explicitly listed in the company's pipeline as a candidate for solid tumors, specific details regarding its molecular target and mechanism of action remain undisclosed as of 2024. The asset represents part of a broader effort by Nanjing Regenecore to leverage mRNA delivery systems to address various malignancies.

Beyond the preview

Go deeper on RT4327.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RT4327.

Explore the full profile